Fly News Breaks for February 5, 2020
Feb 5, 2020 | 07:14 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for Neurocrine Biosciences to $125 from $102 and reiterates a Buy rating on the shares following the company's Q4 results. The analyst believes commercial traction continues to gain momentum for Ingrezza in the treatment of tardive dyskinesia patients. The market opportunity may be significant enough to drive near-term and long-term value for the company, Fein tells investors in a research note.
News For NBIX From the Last 2 Days
There are no results for your query NBIX